Drugs for HER-2-positive Breast Cancer | Buch

Cover: 9783034600934 | Drugs for HER-2-positive Breast Cancer | Maria Sibilia (u. a.) | Buch

Dekorationsartikel gehören nicht zum Leistungsumfang.

Sprache: Englisch

159,95 €*

inkl. MwSt.

Versandkostenfrei per Post / DHL

Lieferzeit 1-2 Wochen

Kategorien:

Der Artikel ist nicht in deutscher Sprache verfasst.
Die Sprache der Produktbeschreibung und Details kann in Englisch angegeben sein. Sollten Sie Verständnisprobleme haben, wenden Sie sich gerne an uns.

Beschreibung

Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.

Zusammenfassung

Contemporary monograph on the treatment of breast cancer.-

Gives a comprehensive account of drugs for HER2-positive breast cancer.-

A valuable source of information for researchers and clinicians from the fields of oncology and pharmacology

Includes supplementary material: [...]

Inhaltsverzeichnis

Drugs for HER-2-positive Breast Cancer: A Major Approval for Translational Cancer Research (Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas Grunt).- The EGFR/ErbB family in breast cancer: from signaling to therapy (Wolfgang J. Köstler and Yosef Yarden).- Trastuzumab as Adjuvant treatment for early stage HER-2 positive breast cancer (Rupert Bartsch and Guenther G. Steger).- Trastuzumab Resistance in breast cancer (Floriana Morgillo, Michele Orditura, Teresa Troiani, Erika Martinelli, Ferdinando De Vita, Fortunato Ciardiello).- Treatment with Trastuzumab beyond Progression (Gunter von Minckwitz and Cristina Pirvulescu).- Pertuzumab - a HER-2 dimerisation inhibitor - for the treatment of breast and other cancers (Giulia Bianchi and Luca Gianni).- Beyond trastuzumab: Second generation targeted therapies for HER2--positive breast cancer (Flavio F. Solca, Guenther R. Adolf, Hilary Jones, Martina M. Uttenreuther-Fischer).

Details

Erscheinungsjahr:	2011
Fachbereich:	Toxikologie
Genre:	Mathematik , Medizin , Naturwissenschaften , Technik
Rubrik:	Wissenschaften
Medium:	Buch
Inhalt:	x 110 S.
ISBN-13:	9783034600934
ISBN-10:	3034600933
Sprache:	Englisch
Herstellernummer:	12548170
Einband:	Gebunden
Autor:	Sibilia, Maria Zielinski, Christoph C. Bartsch, Rupert
Redaktion:	Sibilia, Maria Grunt, Thomas W. Bartsch, Rupert Zielinski, Christoph C.
Herausgeber:	Maria Sibilia/Christoph C Zielinski/Rupert Bartsch et al
Hersteller:	Springer Basel
Verantwortliche Person für die EU:	Springer Basel AG in Springer Science + Business Media, Heidelberger Platz 3, D-14197 Berlin, juergen.hartmann@springer.com
Maße:	241 x 160 x 13 mm
Von/Mit:	Maria Sibilia (u. a.)
Erscheinungsdatum:	07.01.2011
Gewicht:	0,376 kg

Artikel-ID: 101383830